Also in this playlist...
This transcript is automatically generated
Thanks a lot guys now to -- back gonna call with winner and a loser let's first start with the loser.
Groupon is under significant pressure we've talked about the fact that Groupon.
Can't seem to find the growth can't seem to find the customers can't seem to make the revenue and they complain complain about Europe like so many other companies however.
Groupon which had its IPO last year which was -- 31 dollar stock at its highest point is now.
Seven dollars and 36 cents this stock today is over 5% your shareholders all you've done is watch Groupon.
While our let's talk about Merck because -- Merck is actually higher today why that.
A lot of -- news this morning backed -- -- in particular they -- an experimental osteoporosis.
But the experiment was going so well that basically the monitors that have been working on -- -- already recommended stopping it because it's shown that it hasn't backed.
Shown that it reduces.
Risk the name of the -- -- an academy that's what it's called but -- you have the you have Goldman Sachs now.
Raising marks price target to 45 dollars and 41 -- -- new -- The stock today hitting a new annual high ethical sounded pretty -- of some of the other names -- Johnson & Johnson they raise their price target.
Marks and also Bristol-Myers.
And the only -- the -- though was Bristol-Myers yeah.
That is from neutral we got to thank --
Filter by section